[go: up one dir, main page]

WO2012083397A8 - Guanabenz-containing compound for the treatment of primary cutaneous amyloidosis - Google Patents

Guanabenz-containing compound for the treatment of primary cutaneous amyloidosis Download PDF

Info

Publication number
WO2012083397A8
WO2012083397A8 PCT/BR2011/000480 BR2011000480W WO2012083397A8 WO 2012083397 A8 WO2012083397 A8 WO 2012083397A8 BR 2011000480 W BR2011000480 W BR 2011000480W WO 2012083397 A8 WO2012083397 A8 WO 2012083397A8
Authority
WO
WIPO (PCT)
Prior art keywords
guanabenz
primary cutaneous
treatment
cutaneous amyloidosis
containing compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/BR2011/000480
Other languages
French (fr)
Other versions
WO2012083397A1 (en
Inventor
Omar Lupi da Rosa SANTOS
Luis Eduardo Da Cruz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Silvestre Labs Quimica E Farmaceutica Ltda
Original Assignee
Silvestre Labs Quimica E Farmaceutica Ltda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Silvestre Labs Quimica E Farmaceutica Ltda filed Critical Silvestre Labs Quimica E Farmaceutica Ltda
Priority to PCT/BR2011/000480 priority Critical patent/WO2012083397A1/en
Priority to BR112013016044A priority patent/BR112013016044A2/en
Publication of WO2012083397A1 publication Critical patent/WO2012083397A1/en
Anticipated expiration legal-status Critical
Publication of WO2012083397A8 publication Critical patent/WO2012083397A8/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

This invention refers to the pharmaceutical composition with guanabenz as active ingredient and is indicated for the treatment of primary cutaneous amyloidosis. The composition of this invention can be supplied as cream, gel, jelly cream, ointment, lotion or any other dosage form intended for topical use. The effect of guanabenz on the anomalous proteins that cause primary cutaneous amyloidosis, according to this invention, is not related to the action of this drug as alpha-2 adrenergic agonist, as is the case for the other indications of this substance according to the state of the art.
PCT/BR2011/000480 2010-12-22 2011-12-20 Guanabenz-containing compound for the treatment of primary cutaneous amyloidosis Ceased WO2012083397A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/BR2011/000480 WO2012083397A1 (en) 2010-12-22 2011-12-20 Guanabenz-containing compound for the treatment of primary cutaneous amyloidosis
BR112013016044A BR112013016044A2 (en) 2010-12-22 2011-12-20 guanabenzene-containing compound for treatment of primary cutaneous amyloidosis.

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
BRPI10155082-8 2010-12-22
BR020100119505 2010-12-22
PCT/BR2011/000480 WO2012083397A1 (en) 2010-12-22 2011-12-20 Guanabenz-containing compound for the treatment of primary cutaneous amyloidosis

Publications (2)

Publication Number Publication Date
WO2012083397A1 WO2012083397A1 (en) 2012-06-28
WO2012083397A8 true WO2012083397A8 (en) 2013-07-18

Family

ID=45509166

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BR2011/000480 Ceased WO2012083397A1 (en) 2010-12-22 2011-12-20 Guanabenz-containing compound for the treatment of primary cutaneous amyloidosis

Country Status (1)

Country Link
WO (1) WO2012083397A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020222192A1 (en) 2019-05-01 2020-11-05 Clexio Biosciences Ltd. Methods of treating pruritus
EP3962478A1 (en) 2019-05-01 2022-03-09 Clexio Biosciences Ltd. Methods of treating pruritus

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413962B1 (en) 1988-05-02 2002-07-02 N. Eric Naftchi Guanidino compounds effective as anesthetics
US7074834B2 (en) 2000-05-24 2006-07-11 University Of Kentucky Foundation Long acting, reversible veterinary sedative and analgesic and method of use
CA2473102A1 (en) * 2002-01-29 2003-07-29 Protemix Corporation Limited Suppression of cytotoxic protein conformers
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20080275129A1 (en) 2005-03-04 2008-11-06 Acure Pharma Ab Methods and Pharmaceutical Compositions for the Treatment of Neurological Damage
EP1908465B1 (en) * 2006-10-04 2009-04-29 Centre National De La Recherche Scientifique (Cnrs) Use of chlorine guanabenz derivatives for treating prion-based diseases
EP2818184B1 (en) 2007-11-16 2018-10-31 Allergan, Inc. Compositions and methods for treating Purpura

Also Published As

Publication number Publication date
WO2012083397A1 (en) 2012-06-28

Similar Documents

Publication Publication Date Title
WO2012160180A3 (en) Pharmaceutical composition for administration to nails
CA3006294A1 (en) Combinations of rapamycin and metformin for the treatment of joint and skin diseases
MX2013003635A (en) N-heteroaryl compounds.
BRPI0908887B8 (en) liquid pharmaceutical composition, pharmaceutical container, and, methods for preparing and manufacturing a pharmaceutical composition
MX2016009666A (en) Topical delivery of skin compositions having low ph.
IL240283A (en) Veterinary preparations for topical administration containing isoxazoline active substance, methods and uses for the treatment or prevention of infection or parasitic infestation in mammals
WO2014186742A3 (en) Anhydrous hydrogel composition
WO2012143576A3 (en) Compounds for preventing, reducing and/or alleviating itchy skin condition(s)
NZ703808A (en) Topical transdermal dexmedetomidine compositions and methods of use thereof
MY167691A (en) A pharmaceutical spray composition comprising a vitamin d analogue and a corticosteroid
MX2011012143A (en) Compositions suitable for the topical treatment of fungal infections of the skin and nails.
EP2275104A3 (en) Pharmaceutical and cosmetic composition including lactoferrin, ciclopirox and etidronic acid
EP4474011A3 (en) High elasticity hyaluronan compositions and methods of use thereof
WO2015038533A3 (en) Sodium channel modulators for the treatment of pain and diabetes
TN2012000059A1 (en) Compositions comprising tramadol and celecoxib in the treatment of pain
WO2014060638A8 (en) A veterinary method of alleviating noise aversion
WO2012154122A3 (en) A topical formulation for treatment of hyperkeratotic skin
EP2361083A4 (en) Composition for treatment of epithelial tissue
WO2015001163A3 (en) Lipid nanoparticles for healing wounds
BR112015027436A2 (en) Topical composition and carrier for administration of pharmaceutically or cosmetically active ingredients
BR112012021445B8 (en) pharmaceutical or neutroceutical formulation, and use of a bioavailability promoting agent
MX357704B (en) O/w-emulsion-type topical pharmaceutical compositions containing a retinoid.
WO2012083397A8 (en) Guanabenz-containing compound for the treatment of primary cutaneous amyloidosis
WO2013182998A4 (en) Cosmetic and / or pharmaceutical composition for the treatment of skin inflammation and related syndromes
WO2009147326A8 (en) Analgesic effects of peptide toxin apetx2

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11810999

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11810999

Country of ref document: EP

Kind code of ref document: A1

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013016044

Country of ref document: BR

ENP Entry into the national phase in:

Ref document number: 112013016044

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20130621